Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Freie Akademische Gesellschaft Basel | UNKNOWN |
Not provided
Not provided
Not provided
Not provided
This study is to evaluate the sensitivity and intra-/inter-observer agreement of the averaged magnetization inversion recovery acquisitions (AMIRA) in spinal cord (SC) Multiple sclerosis (MS) lesion detection and to evaluate the additional clinical value of this sequence in clinical settings.
An averaged magnetization inversion recovery acquisitions (AMIRA) sequence was proposed for SC MRI. This MR-sequence delivers excellent contrast between the SC gray and white matter as well as between the SC and cerebrospinal fluid (CSF) in clinically feasible-acquisition times. Moreover, the high quality and in-plane resolution of AMIRA images allows for segmentation of the SC gray and white matter with high accuracy and reproducibility. This study is to evaluate the sensitivity and intra-/inter-observer agreement of the averaged magnetization inversion recovery acquisitions (AMIRA) in spinal cord (SC) Multiple sclerosis (MS) lesion detection and to evaluate the additional clinical value of this sequence in clinical settings.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Spinal Cord MRI | Experimental |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| SC MRI | Procedure | SC MRI (Averaged Magnetization Inversion Recovery Acquisitions (AMIRA), standard conventional SC MRI sequences, additional sequences for spinal cord MRI (sagittal-2D or 3D short tau inversion recovery, sagittal-2D or 3D phase-sensitive inversion recovery, 3D magnetization prepared 2 rapid acquisition gradient echoes (MPRAGE)). To evaluate the presences of ongoing inflammation (acute or chronic) in the SC of patients, 3D MPRAGE and 3D fluid-attenuated inversion recovery images after intravenous gadolinium (Gd) contrast administration (0.1 mmol per kg body weight) will be acquired. |
| Measure | Description | Time Frame |
|---|---|---|
| Number of SC lesions | Number of SC lesions using AMIRA compared to gold-standard conventional SC MRI sequences | one time assessment (60 minutes scheduled per patient for the MRI part including preparation time outside of the scanner and actual scanning time) |
| Inter-observer agreement on SC lesion count | Inter-observer agreement with regard to lesion detection using AMIRA compared to gold-standard conventional SC MRI sequences. | one time assessment (60 minutes scheduled per patient for the MRI part including preparation time outside of the scanner and actual scanning time) |
| Presence of ongoing inflammation (acute or chronic) in the SC | Presence of ongoing inflammation (acute or chronic) in the SC 3D MPRAGE and 3D fluid-attenuated inversion recovery images after intravenous gadolinium (Gd) contrast administration (0.1 mmol per kg body weight) | one time assessment (60 minutes scheduled per patient for the MRI part including preparation time outside of the scanner and actual scanning time) |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
. History of severe (other) neurological, internal or psychiatric disease with SC affection
MRI-related exclusion criteria (questionnaire):
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Katrin Parmar, PD Dr. med. | Contact | +41 61 83 65 214 | katrin.parmar@unibas.ch | |
| Charidimos Tsagkas, Dr. med. | Contact | charidimos.tsagkas@usb.ch |
| Name | Affiliation | Role |
|---|---|---|
| Katrin Parmar, PD Dr. med. | University Hospital Basel, Department of Neurology | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University Hospital Basel, Department of Neurology | Recruiting | Basel | 4031 | Switzerland |
Not provided
| ID | Term |
|---|---|
| D009103 | Multiple Sclerosis |
| ID | Term |
|---|---|
| D020278 | Demyelinating Autoimmune Diseases, CNS |
| D020274 | Autoimmune Diseases of the Nervous System |
| D009422 | Nervous System Diseases |
| D003711 | Demyelinating Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D000073222 | Patient Health Questionnaire |
| ID | Term |
|---|---|
| D011795 | Surveys and Questionnaires |
| D003625 | Data Collection |
| D004812 | Epidemiologic Methods |
| D008919 | Investigative Techniques |
Not provided
Not provided
All participants (embedded within the currently ongoing Swiss MS Cohort (SMSC) study) will undergo a single visit including a clinical interview, neurological examination and MRI.
Not provided
Not provided
Not provided
Not provided
|
| patient questionnaire | Other | 12-item multiple sclerosis walking scale (MSWS-12) questionnaire: self-report measure of the impact of MS on the individual's walking ability |
|
| D001327 | Autoimmune Diseases |
| D007154 | Immune System Diseases |
| D011581 | Psychological Tests |
| D004191 | Behavioral Disciplines and Activities |
| D017531 | Health Care Evaluation Mechanisms |
| D011787 | Quality of Health Care |
| D017530 | Health Care Quality, Access, and Evaluation |
| D011634 | Public Health |
| D004778 | Environment and Public Health |